Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Reinwald, Mark ^a   Schleyer, Eberhard ^b,c   Kiewe, Philipp ^d   Blau, Igor Wolfgang ^d   Burmeister, Thomas ^d   Pursche, Stefan ^b   Neumann, Martin ^d   Notter, Michael ^d   Thiel, Eckhard ^d   Hofmann, Wolf Karsten ^a   Kolb, Hans Jochem ^e   Burdach, Stefan ^e   Bender, Hans Ulrich ^e  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Klinikum Merseburg   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DASATINIB; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERFERON; NILOTINIB; PONATINIB; RITUXIMAB; VINCRISTINE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKEMIA RELAPSE; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; TREATMENT RESPONSE; YOUNG ADULT; ALLOTRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; BENZAMIDES; CENTRAL NERVOUS SYSTEM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84904098308     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/637059     Document Type: Article

References (17)

1. Pfeifer H., Wassmann B., Hofmann W.-K., Komor M., Scheuring U., Brück P., Binckebanck A., Schleyer E., Gökbuget N., Wolff T., Lübbert M., Leimer L., Gschaidmeier H., Hoelzer D., Ottmann O. G., Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical Cancer Research 2003 9 13 4674 4681 2-s2.0-10744223495 (Pubitemid 37336441)
2. Sanders K. E., Ha C. S., Cortes-Franco J. E., Koller C. A., Kantarjian H. M., Cox J. D., The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer 2004 100 10 2176 2180 2-s2.0-2342501796 10.1002/cncr.20280 (Pubitemid 38580337)
3. O'Hare T., Walters D. K., Stoffregen E. P., Jia T., Manley P. W., Mestan J., Cowan-Jacob S. W., Lee F. Y., Heinrich M. C., Deininger M. W. N., Druker B. J., In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research 2005 65 11 4500 4505 2-s2.0-21144451094 10.1158/0008-5472.CAN-05-0259 (Pubitemid 40740783)
4. Gabert J., Beillard E., van der Velden V. H. J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J. M., Cavé H., Pane F., Aerts J. L. E., De Micheli D., Thirion X., Pradel V., González M., Viehmann S., Malec M., Saglio G., van Dongen J. J. M., Standardization and quality control studies of "real time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer Program. Leukemia 2003 17 12 2318 2357 2-s2.0-9144222001 10.1038/sj.leu.2403135 (Pubitemid 38072573)
5. Thiede C., Bornhäuser M., Oelschlägel U., Brendel C., Leo R., Daxberger H., Mohr B., Florek M., Kroschinsky F., Geissler G., Naumann R., Ritter M., Prange-Krex G., Lion T., Neubauer A., Ehninger G., Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001 15 2 293 302 2-s2.0-17744376761 10.1038/sj.leu.2401953 (Pubitemid 32175467)
6. Pursche S., Ottmann O. G., Ehninger G., Schleyer E., High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2007 852 1-2 208 216 2-s2.0-34249667739 10.1016/j.jchromb.2007.01.019 (Pubitemid 46830984)
7. Porkka K., Koskenvesa P., Lundán T., Rimpiläinen J., Mustjoki S., Smykla R., Wild R., Luo R., Arnan M., Brethon B., Eccersley L., Hjorth-Hansen H., Höglund M., Klamova H., Knutsen H., Parikh S., Raffoux E., Gruber F., Brito-Babapulle F., Dombret H., Duarte R. F., Elonen E., Paquette R., Zwaan C. M., Lee F. Y. F., Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system philadelphia chromosome positive leukemia. Blood 2008 112 4 1005 1012 2-s2.0-51649111035 10.1182/blood-2008-02-140665
8. Takayama N., Sato N., O'Brien S. G., Ikeda Y., Okamoto S.-I., Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology 2002 119 1 106 108 2-s2.0-0036399992 10.1046/j.1365-2141.2002.03881.x (Pubitemid 35176504)
9. Togashi Y., Masago K., Masuda S., Mizuno T., Fukudo M., Ikemi Y., Sakamori Y., Nagai H., Kim Y. H., Katsura T., Mishima M., Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 2012 70 3 399 405 2-s2.0-84866364723 10.1007/s00280-012-1929-4
10. Reman O., Pigneux A., Huguet F., Vey N., Delannoy A., Fegueux N., de Botton S., Stamatoullas A., Tournilhac O., Buzyn A., Charrin C., Boucheix C., Gabert J., Lhéritier V., Vernant J.-P., Fière D., Dombret H., Thomas X., Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leukemia Research 2008 32 11 1741 1750 2-s2.0-47249115216 10.1016/j.leukres. 2008.04.011
11. + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007 109 1 306 314 2-s2.0-33846018356 10.1182/blood-2006-03-013250 (Pubitemid 46053071)
12. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J. D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O. G., Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. The New England Journal of Medicine 2006 354 24 2542 2551 2-s2.0-33745086350 10.1056/NEJMoa055104 (Pubitemid 43882350)
13. + ALL). Blood 2005 106 2 458 463 2-s2.0-22144460555 10.1182/blood-2004-05-1746 (Pubitemid 40981238)
14. Merante S., Colombo A. A., Calatroni S., Rocca B., Boni M., Bernasconi P., Bonvini L., Soverini S., Alessandrino E. P., Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplantation 2009 44 4 263 264 2-s2.0-69749124900 10.1038/bmt.2009.6
15. + ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia Research 2009 33 1 174 177 2-s2.0-55049088837 10.1016/j.leukres.2008. 03.031
16. Jabbour E., Hochhaus A., Cortes J., La Rosée P., Kantarjian H. M., Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010 24 1 6 12 2-s2.0-74149095067 10.1038/leu.2009.193
17. Garg R. J., Kantarjian H., O'Brien S., Quintás-Cardama A., Faderl S., Estrov Z., Cortes J., The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009 114 20 4361 4368 2-s2.0-73349100015 10.1182/blood-2009-05-221531